You can buy or sell iCAD and other stocks, options, ETFs, and crypto commission-free!
iCAD, Inc. engages in the provision of advanced image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer. It operates through the Cancer Detection and Cancer Therapy business segments. Read More The Cancer Detection segment includes image analysis and clinical decision support solutions for mammography, breast tomosynthesis, and computed tomography imaging. The Cancer Therapy segment offers an isotope-free cancer treatment platform technology. The company was founded in 1984 and is headquartered in Nashua, NH.
Nashua, New Hampshire
52 Week High
52 Week Low
Simply Wall StMar 21
Does iCAD, Inc. (NASDAQ:ICAD) Have A High Beta?
Anyone researching iCAD, Inc. (NASDAQ:ICAD) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. The first type is company specific volatility. Investors use diversification across uncorrelated stocks to reduce this kind of price volatility across the portfolio. The other type, which cannot be diversified away, is the volatility of the entire market. Every stock in the market...
Seeking AlphaMar 19
iCAD, Inc. (ICAD) CEO Michael Klein on Q4 2018 Results - Earnings Call Transcript
iCAD, Inc. (NASDAQ:ICAD) Q4 2018 Earnings Conference Call March 18, 2019 4:30 PM ET Company Participants Jeremy Feffer - IR Michael Klein - Chairman and CEO Stacey Stevens - Chief Strategy and Commercial Officer Scott Areglado - Interim CFO Conference Call Participants Francois Brisebois - Laidlaw Per Ostlund - Craig-Hallum Capital Operator Greetings, welcome to the iCAD, Incorporated Fourth Quarter and Full Year 2018 Earnings Conference Call. [Operator Instructions] Please note, this conference i...
Associated PressMar 18
iCAD Reports Fourth Quarter and Full-Year 2018 Financial Results
Company achieved key milestone in fourth quarter with FDA clearance and subsequent U.S. commercial launch of ProFound AI™ for digital breast tomosynthesis Conference call today at 4:30 p.m. ET NASHUA, N.H. , March 18, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported financial results for the three and 12-months ended December 31, 2018. Fourth Quarter 2018 Highlights: -- Total revenue of appr...
-$0.10 per share
-$0.07 per share